Coupling factor 6-induced activation of ecto-F^sub 1^F^sub o^ complex induces insulin resistance, mild glucose intolerance and elevated blood pressure in mice

• Published in: Diabetologia Vol. 55; no. 2; p. 520
• Main Authors: Osanai, T, Tanaka, M, Magota, K, Tomita, H, Okumura, K
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer Nature B.V 01.02.2012
• Subjects: Acidosis; Angiogenesis; Blood pressure; Cardiovascular disease; Diabetes; Glucose; Hypertension; Insulin resistance; Ischemia; Kinases; Mitochondria; Mortality; Musculoskeletal system; Peptides; Phosphorylation; Plasma; Public health; Transgenic animals
• DOI: 10.1007/s00125-011-2341-z
• ISSN: 0012-186X

Despite advances in pharmacological treatments, diabetes with hypertension continues to be a major public health problem with high morbidity and mortality rates. We recently identified a circulating peptide coupling factor 6 (CF6), which binds to the plasma membrane ATP synthase (ecto-F^sub 1^F^sub o^ complex), resulting in intracellular acidosis. We investigated whether overexpression of CF6 contributes to diabetes and hypertension by intracellular acidosis. Transgenic mice overexpressing CF6 (also known as ATP5J) were generated, and physiological, biochemical and molecular biology studies were performed. CF6 overexpression elicited a sustained decrease in intracellular pH in tissues (aorta, kidney, skeletal muscle and liver, with the exception of adipose tissue) that express its receptor, the β-subunit of ecto-F^sub 1^F^sub o^ complex. Consistent with the receptor distribution, phospho-insulin receptor β, phosphoinositide 3-kinase activity and the phospho-Akt1:total Akt1 ratio were all decreased in the skeletal muscle and the liver in transgenic compared with wild-type mice, resulting in a decrease of plasma membrane-bound GLUT4 and an increase in hepatic glucose production. Under a high-sucrose diet, transgenic mice had insulin resistance and mild glucose intolerance; under a high-salt diet, they had elevated blood pressure with increased renal RAS-related C3 botulinum substrate 1 (RAC1)-GTP, which is an activator of mineralocorticoid receptor. Through its action on the β-subunit of ecto-F^sub 1^F^sub o^ complex, which results in intracellular acidosis, CF6 plays a crucial role in the development of insulin resistance and hypertension. This finding might advance our understanding of the mechanisms underlying diabetes and hypertension, possibly also providing a novel therapeutic target against cardiovascular disease.[PUBLICATION ABSTRACT]